Table 1 Characteristics of patients with asthma by age group
Variable | Group A: < 65 years N = 1240 (72.5%) | Group B: 65–74 years N = 282 (16.5%) | Group C: ≥75 years N = 189 (11%) | p |
|---|---|---|---|---|
Sex (% women)a | 67.8% | 68.8% | 72.9% | 0.397 |
Active smokersa | 13.7% (N = 163/1185) | 3.7% (N = 10/272) | 0.5% (N = 1/186) | <0.001 |
Ex-smokersa | 23.8% (N = 282/1185) | 21.3% (N = 58/272) | 17.7% (N = 33/186) | <0.001 |
Obesea (BMI > 30 kg/cm2) | 25.5% (N = 299/1171) | 45.8% (N = 125/273) | 44.3% (N = 82/185) | <0.001 |
Diagnosed with difficult-to-control asthmaa | 15.3% (N = 190/1240) | 14.2% (N = 40/282) | 7.9% (N = 15/189) | 0.027 |
FEV1 < 50%a | 7.0% (N = 74/1064) | 13.7% (N = 34/249) | 16.7% (N = 28/163) | <0.001 |
FEV1 < 50% | 54.4% (N = 74/136) | 25% (N = 34/136) | 20.6% (N = 28/136) | <0.001 |
FeNO > 30 ppb | 89.9% (N = 160/178) | 8.4% (N = 15/178) | 1.7% (N = 3/178) | <0.001 |
Received ≥2 corticosteroid cycles in the previous year | 70.9% (N = 310/437) | 19.7% (N = 86/437) | 9.4% (N = 41/437) | 0.106 |
Treated with high doses of inhaled corticosteroidsb | 60.8% (N = 236/388) | 20.9% (N = 81/388) | 18.3% (N = 71/388) | 0.045 |
Treated with antileukotriene agents | 33% (N = 387/1173) | 42.9% (N = 115/268) | 27.8% (N = 52/187) | 0.001 |
Treated with omalizumab | 76.4% (N = 304/398) | 18.1% (N = 72/398) | 5.5% (N = 22/398) | 0.288 |